OvaScience Strengthens Management Team to Support Expanding Global Operations
- Promotes Arthur Tzianabos, Ph.D., to President; Appoints New Head of Commercial -
“Arthur’s ability to rapidly translate our EggPC technology into
fertility treatment options for patients led to the significant progress
we made this year,” said
“We are delighted to have David join our team. David’s extensive global expertise in women’s health will support the Company as we continue to provide the AUGMENT treatment to patients and plan for the international launch of the OvaPrime treatment in 2015,” said Dr. Dipp.
“Theresa has been a key driver in elevating awareness of
In conjunction with Mr. Harding’s appointment, the Company reported an
inducement option grant to Mr. Harding in accordance with NASDAQ Listing
Rule 5635(c)(4). The award was approved by the Board's Compensation
This press release includes forward-looking statements about the Company’s plans for the AUGMENT treatment and its two fertility treatments in development, and the Company’s plans to make the AUGMENT treatment available to more patients, launch OvaPrime in 2015 internationally and advance development of the OvaTure treatment. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.